Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To Allo. How did you think they raised $80 million without diluting. Controller again? Or dark pools?
A classic post by the chosen one.
Oct 27. The day the flame went out. Post 7790. Wow you'd think you'd be able to read a report correctly. And the kicker. He thought it wouldn't dilute if it happened. But we are the ones without a clue. LMBO
"Good News ! According To The Immediate Report Released Today They Were Able To Sell The 80 Million Dollars Worth Of Stock In The United States ! They Now Have The Big Coin For The Big Deal ? IMO
Wow ! They Must Have Sold Some Big Share Blocks To Institutional Investors ? I Bet The Tute Ownership Far Exceeds 15 % Now ?
As of October 29, 2017, prior to the consummation of this offering, we were deemed to have sold $80,000,000 of securities under the foregoing "shelf" registration statement
Report Released Today ! Only 108 Million Shares Outstanding Shares After Today ! That is Very Small For A Potential Big Biotech Company ! "
Or how about this one on the same day. Even better. Post 7641. When did they open shop. How long before we hear of the massive global expansion plan. You think a lot like management. Cart before the horse. Or did we get something approved and we can't manufacture ourselves?
"I Have To Disagree, Lonza Setting Up Shop In Haifa is Just Way Too Coincidental ! IMO.. It's All Part Of A " Master Global Expansion Plan". We Shall See. "
So we should rule them out on being the controller? Or are they the ones waiting for the BIG DEAL!!!!LMBO Almost forgot. Ohhhhh. Awwwww.
Like an old plant or a seedling. Delete.
Stale when it first aired and still stale now.
That's your idea of proof. Is Pluristem mentioned? Didn't think so. Try again.
Likewise why can it not just be the normal markets? These dark pools are utilized for other stocks right. So why make that giant, extremely unlikely, leap that it's a controller. You have given absolutely zero proof of a controller. But yet you think we can provide proof that it's not. Give us evidence.
The fact dark pools exist is not proof. Because Pluristem may or may not be traded on these dark pools is not. Trades of 100 or 200 shares at a time are not proof. Happens everywhere. The fact that our share price is so low is most definitely no proof. Our twins and how they choose to make things up, and how they attempt to figure it out on the fly and will hire and promote just about anyone have been the ONLY reasons our share price is this low.
But again, there's always a chance you might be right for the first time. About as likely as me thinking this management is capable in the least.
Many years of waiting for this signing to happen. You would think of a big Pharma truly wanted this, they would make an offer. It's not like they are known to be frugal. Don't remember any of them offering more than a few bucks for any company. So can't imagine them spending anything more than that for the breakthrough technology that we have. It probably is legal for them to manipulate price like you say. That's why they're using the dark pools to do all the legal trades right.
The controller will just keep on doing this as long as it takes. They know with the elite management we have, they won't run this to the ground. They know there's no others in our space. No competition at all. They are so far behind, nothing matters. Must thwart Pluristem until we sign the deal of the century.
But you're probably right. You've been right so often, it must be the case. Ohhhh. Awwwww.
Yes another one to add to the greatest hits list. Right up there with Pluristem selling shares to support the price, or Lonza wanting to partner so they can get Pluristem as their customer, or missing time slots in shows, countless this would be a great show to release news, or the sold the entire $80 million via the ATM. So many. Thank you again Allo for your insightful posts. Your thoughts are so valid and well thought out. Ohhh. Awwww. Can't wait for you know who's greatest post if the day.
I guess you're anxious to buy lower too there eh Saud, according to the post you made I'm replying to. 25,000 shares at $1.87. Seems both you and Zzatt are in the same boat.
Surprised there's not a position of Manager for the Creation of Positions. Better not say it too loudly and give them any ideas. I think the bookkeeper is due for a promotion.
Found a link on zoominfo which has a list of some of the employees at Pluristem. Found it from searching the new face on the presentation, Boaz Leshem. Have a look at some of the titles. This ones my favourite. "Human resources training manager". And we now know what takes up a lot of the twins times. Making up titles so most can be called managers.
https://www.zoominfo.com/pic/pluristem-therapeutics-inc/343607397
First look I've seen into some of there employees.
Here's some great experience for you for one I looked at.
Tammy Sharon. Homeland Defence Projects Manager.
Experience. Rambam Medical Center, Pluristem Life Systems.
Thanks for answering the question with the only answer possible, unlike the giant plant.
So I would assume you are in agreements with me, making 2 out of 11 milestones as I've pretty much proven. If you have other data please correct me.
Now how does one not question everything when it comes to transparency, credibility, business acumen, absolutely anything? When a CEO comes out and states such a fictitious statement, how does that make you feel positive in the least for his ability to run a company. Or that any kind of milestone or anything they out out there has any kind of truth to it. How should analysts take this statement, or any potential investor? How can they actually say this with a straight face? It's unbelievable. And for anyone not to be outraged as I am? Astonishes me even more.
And thank you and EichKing as well Blue. The 3 amigos of truth. .
LMAOx200,000. Wow you can think of anything. Maybe the long arms of the controller, got to the news wires and changed the writing from hardly any to most, trying to throw the final blow to Zami's near extinguished credibility. Hilarious. But thank you so much Allo. Ohhhhhh awwwwwweeee. My hero.
To: Allo, FDApproved, Allogeneic, Disruptive. I've asked you this on other boards, but you just delete them.
What do you think of Zami stating they made most of their milestones in 2017. Was that truthful? There's much more to say about this question as I've stated many times. Funny I have yet to here a single response from anyone i pose this question to. This question can go to anyone. Care to throw your thought in there too MC, considering you say my questions get answered. Oh and Allo, feel free to ask the boss how to respond.
And yes Allo, Celgene saw the powerhouse of a company Pluristem and thought, we better back off. They have TWO ceo's. They came into our boardroom and we couldn't make a thing out they were saying. I think one of them tooted. Powerful people!!! Better not mess. I did get a free first aid kit for my car though.
Funny how resumes have changed over the years. Taken from 2005 report
Israel Ben Yoram.
Mr. Ben-Yoram was appointed a director on January 26, 2005. Mr. Ben-Yoram has been a director and partner in the accounting firm of Mor, Ben-Yoram and Partners in Israel since 1985 to now. This accounting firm currently employs over 15 employees in the field of auditing, consulting, and accompanying projects. Since 1992 to now, Mr. Ben-Yoram has also served as a shareholder and the head director of Mor, Ben-Yoram Ltd., a private company in Israel in parallel to the operation of the Mor, Ben-Yoram and Partners accounting firm. This company provides management services, economic consulting services and other professional services to businesses. Mr. Ben-Yoram received a B.A. in accounting from the University of Tel Aviv, an M.A. in Economics from the Hebrew University of Jerusalem, an LLB and an MBA from Tel Aviv University and an LLM from Bar Ilan University.
https://www.sec.gov/Archives/edgar/data/1158780/000108503705001381/f10ksb063005.htm
Then in 2011 it changed for some reason.
Mr. Ben-Yoram became a director of the Company in January 2005. He has been a director and partner in the accounting firm of Mor, Ben-Yoram and Partners in Israel since 1985. In addition, since 1992, Mr. Ben-Yoram has been a shareholder and has served as the head director of Mor, Ben-Yoram Ltd., a private company in Israel in parallel to the operation of Mor, Ben-Yoram and Partners. This company provides management services, economic consulting services and other professional services to businesses. Furthermore, Mr. Ben-Yoram is the CEO of Eshed Dash Ltd. and Zonbit Ltd. During 2003-2004 Mr. Ben-Yoram served as a director of Brainstorm Cell Therapeutics Inc. (BCLI) and Smart Energy solutions, Inc. (SMGY), both of which were traded on the NASDAQ. Mr. Ben-Yoram received a B.A. in accounting from the University of Tel Aviv, an M.A. in Economics from the Hebrew University of Jerusalem, an LL.B. and an MBA from Tel Aviv University and an LL.M. from Bar Ilan University. In addition, Mr. Ben-Yoram is qualified in arbitration and in mediation.
We believe that Mr. Ben-Yoram’s qualifications to sit on our Board of Directors include his years of experience in the high-tech industry, his experience serving as a director of NASDAQ companies, as well as his knowledge and familiarity with corporate finance and accounting.
https://www.sec.gov/Archives/edgar/data/1158780/000117891311002580/zk1110396.htm
This is where the addition of Braintech and Smart Energy come into his resume, referring to 2003-2004. Did he forget he was a director in 2005, and then suddenly remembered in 2011? And funny how the firm he is partner in has had 15 employees since at least 2005. That statement remains on his bio today on Pluristem’s website. What growth. What business prowess. Fine resume for a director of the paradigm shifting, earth shattering, juggernaut in the making, Pluristem. And of course you remember but refuse to comment, that Braintech wasn’t formed until 2004 and Smart Energy on 2007. And no mention of him being a director in either of these companies has been found.
See what you can find when you search for this plan from 2005 where the amount of options being available today was created. No luck finding it as of yet. Hate to see what other surprises could be lurking in this “plan”
But again, I’m “ok” with them.
Like I said Blue their biggest gaff by far. Have the technology over a decade ago, and miss the boat entirely. A huge market like the manufacturing side, does not go unnoticed. Others with deep pockets will figure it out.
And they go ahead and waste 2 years building out their manufacturing to do nothing with it. Let's not only dismiss a breakthrough technology at the time, but waste 2 years doing it, delaying the direction you chose to take. Let competition catch up or pass by on both fronts. Smart leadership I guess.
Trying to sell first aid kits for cars, would not bring on competition for obvious reasons. But a 4 billion dollar market that they saw and stated in their reports in 2005 would. Why did they not go after this is beyond me.
Yes excellent post Zzatt. Ohhhhhhhh. You're best yet!!! You miss the point of competition but what else is new.
You know there are risks eh? I would love to hear your views on the risks they face. Not just a sentence or two. There are a lot of risks and based on your last post, you can try sometimes to write actual thoughts. Or do you think they're minimal, which you're avoidance of real questions suggests.
And one more question. What do you think of Zami coming out and saying they made MOST of their milestones in 2017. My count is 2 out of 11, based on January's presentation in 2017. Do you have any info that can back up that statement? Are you "ok" with him making a joke of himself by stating such erroneous facts. Or is that what you would expect from some "smart" leaders. Do you think that was smart? Or delusional which is the best way to describe it.
You avoid management topics like the plague. So hopefully you will answer this one, just this one time, for me. And feel free to put any management issues into the risk section if you think there's any.
Unfortunately, I will have to wait U til tomorrow to see your avoidance of questions again. LMBOx200,000
Hi Gary,
So are you going to give us an example of a drug that the DOD got before FDA approval. The FDA routinely allows this as you say. I am just curious if you happened to remember the stock you were invested in and they were allowed to do this?
This was the whole reason for this bill last year, or so I though. Military wanted freeze dried plasma among a couple of other things. Then some make the huge leap to them wanting ARS. Sadly, it wasn't. Nor was it surprising, considering the chosen one started the herd hoping.
Most on this board misses that exact point. Some more than others. Change upper management and most of our complaints would be gone.
See they were on the right track in 2005. Identified a huge market and a need to match. But somehow, went in another direction. Again, from 2005. Imagine 12 years later where we would be?
There are presently between 40,000 to 50,000 bone marrow transplants performed annually worldwide. Approximately 18,000 of these bone marrow transplants are performed in the United States and approximately 25,000 are performed in Europe. We have not taken steps to determine the number of bone marrow transplants
performed elsewhere. Of the 40,000 to 50,000 bone marrow transplants performed, only 5,000 are performed on babies and children. Furthermore, most of these 40,000 to 50,000 bone marrow transplants are allogeneic transplants, requiring patients to locate donors with compatible hematopoietic stem cells. Based on the fact that only one in three patients actually finds a compatible donor, we estimate that the number of potential bone marrow transplants should exceed 150,000 annually. Based on these statistics, we believe that the existing methods of transplanting human bone marrow have not been perfected and are far from reaching an ideal level of success.
Presently, the standard bone marrow transplant procedure costs approximately $100,000 per patient. This translates into approximately $5 billion annually that patients and their medical insurers around the world are spending currently for this procedure alone. In addition, to manage the risk of incompatibility between donor and patient stem cells, a separation procedure of the stem cells is frequently also performed at a cost of $70,000. We believe that 15% to 20%, or 15,000 to 20,000 of the patients require this stem cell separation procedure as well, adding a further $700 million to the current spending on bone marrow transplants in the United States. Combining these figures with similar expenditures in Europe and Asia, we estimate the current worldwide spending on bone marrow transplants to exceed $7 billion per year.
We estimate that there are more than 50 cord blood banks in the world, most of them located in the United States. In 2001, they collected cryo-preserved (frozen) and stored cord blood from some 34,000 to 36,000 donors and they project that the annual rate of growth of cord blood preserved will be over 15%. Due to the increased use of umbilical cord blood hematopoietic stem cells in bone marrow transplants, we expect that the number of cord blood banks will also grow significantly around the world. We also expect that, in developed countries, in the near future, umbilical cord blood may be drawn at the time of every birth and stored for later use. We believe that the stem cell expansion technology that we will make available through our PluriX™ Bioreactor system, together with proper marketing efforts, will increase the number of umbilical cord blood donors for personal use, i.e., parents storing the umbilical cord blood for their children's future, by increasing the existing growth rate. This will also provide a full base of hematopoietic stem cells donor opportunities to patients throughout the world. We project that the global market for the provision of stem cell expansion services can reach approximately $4 billion.
[/b
But we have given the competition 12 freaking years to catch up.
Seems like they can grow other types of cells in the Bioreactors. Unless they were lying in their report. So yes manufacturing possibilies have been wasted for years. Biggest gaff this company has made to date. Would have been able to fund all their trials with no need for dilution, or not nearly to the extent they have. Could have been the leader in this field, but chose to keep it to themselves and build a big plant so they can all watch through the glass like kids at a candy store, and grow little or next to nothing. Impresses the ladies I heard though.
And did you notice the $50,000 in revenue this quarter at a cost of $2,000. No margins there. Manufacturing is a waste of time. No money to be made there. Besides, we can always dilute.
•Our PluriX™ Bioreactor system can be used to expand umbilical cord blood hematopoietic stem cells for use in adult transplants. With the assistance of our PluriX™ Bioreactor system, one portion of umbilical cord blood hematopoietic stem cells can be expanded to quantities enough for a number of transplants. This means that healthy autologus umbilical cord blood hematopoietic stem cells can be taken at the time of birth, expanded into mature hematopoietic stem cells and stored by a cell bank in the instance that it may be needed by that specific patient at a later date. This will eliminate the current practice of transplanting cancerous cells back into the patient.
•Our PluriX™ Bioreactor system can be used for allogenic expansion, i.e. to expand the hematopoietic stem cells from donors other than the patient himself. Allogenic stem cells can also be expanded for use as a transplant source for adults in the instances that enough stem cells are not attainable from a particular donor.
•Our PluriX™ Bioreactor system can also be used for autologus proliferation, i.e. to expand the hematopoietic stem cells taken from the transplant patients themselves. Contrary to any existing available technologies known to us, our PluriX™ Bioreactor system will allow the use of autologus bone marrow transplantation in the case that healthy cells are not clearly attainable from the patient.
https://www.sec.gov/Archives/edgar/data/1158780/000108503704001033/f10ksb063004.htm
Sure did make them look foolish. But I bet when the next presentation comes out, it will be in there. Zero credibility whatsoever. And getting worse if that's even possible.
I will second that NOT allo you have never been right once in any of your statement. Not ONCE!!! But we should think this time it's going to happen. And I will be here until the end as well, willing and easily able to discount feeble attempts to justify this pathetic management and board.
Exactly with regards to no bad results. I told them to read the Edison report. Totally oblivious to it all. No comment at all. Just ignore. Here are some parts that were obviously ignored
To date, the company has not achieved any statistically significant results for an approvable endpoint in any of its programs.
We expect that the company will require $50m in additional capital, in addition to any development grants, to reach profitability in 2020. This value may increase dramatically if the company is unable to secure a procurement contract for PLX-R18 at that time
CLI... There is a high degree of variability for AFS reported in the literature, and the rate appears to have been increasing since the mid-1990s due to higher rates of revascularization procedures as well as better diabetes control, antiplatelet therapy, infection control and smoking cessation.
Hip trial...PLX-PAD has been studied in a single Phase I/II study in patients following elective THR, which reported results in January 2014. It should be noted that this indication is different to current hip injury indication and included patients that opted for THR as a treatment for osteoarthritis. These patients have a significantly higher quality of life and lower morbidity than patients following hip fracture.
So how do you make a statement like routinely, when you can't even give a real example. You were invested in a stock. Can't go back and look to see what drug you are talking about. Or military recollection. Doesn't really cut it sorry. So please try to look for an actual verifiable example. One with a link for all of us to see. Surely at least one must be easily found, since it's routinely done. So care to give it another try, or admit it was embellished or made up entirely. TIA
Care to give us examples of the unapproved drugs the DOD has routinely purchased like you say. TIA.
That's what zome have been saying since $2. Look where it's got them.
Zero correlation sorry.
Been in this far too long and still believe in the products potential. But we need new management asap.
Logic? Too funny. Ignoring who runs this thing defies logic. Can't get to the $30's if you can't run it. Why not start with $2? Can't even make it there without a raise in sight. The one where Zzatt was buying intoamd bragging about it. Anything under $2's a steal. LMBOx200,000. Kind of like playing the lottery...could win a million, even if the odds are stacked against you. But ignore the fact that management is incapable.
"So you're telling me there's a chance".
Why wait for the $1.20's. We could be under a buck soon if they keep missing the "we'll get em next week".
I think mozt are cut from the same cloth here EichKing. No other way to explain the posts on this board.
Just keep ignoring any questions on the absolute lack of experience of management or board, questionable resumes to say the least, the many gaffs, delayed milestones, selling into news, horrific shareholder update, on and on, that have been pointed out, with new revelations each week to substantiate the argument. Zero evidence that states otherwise. Anyone can run a company right? It's Biotech. Jokes.
I'm "ok" with them. Silence is deafening!!! LMBOx200,000
It's so smack right in your face I don't comprehend how anyone could miss it. To say they made most milestones if delusional truly. They MISSED a vast majority of their milestones.
Too bad we have an accountant trying to keep the leader in check, not a whole Republican Party. Or too bad CEO's don't have to do a yearly physical. Are they planning to parade the vials of "cures" down the streets of Haifa? My vials bigger than yours. When is Zami going to start tweeting to his base of supporters. LMBO.
What is happening to this world?
You're right my bad. But it just states it must be reported, which it was on June 6. Not sure of the delay allowed to report, but again, it stinks.
Unfortunately with our crappy price, even with 13,000 shares, a double doesn't put them over the $50,000 threshold. But it is still rotten. Just a quick $13 grand under the radar of the SEC. These guys know what they're doing when it comes to self enrichment. Only thing there good at.
And look at this from the S-8 that was just reported.
"Pursuant to the 2005 Plan, the number of shares of Common Stock of the Company made available under the 2005 Plan shall be automatically increased to be equal to 16% of the number of shares of Common Stock issued and outstanding of the Company on a fully diluted basis immediately prior to the grant of securities."
Still following this "plan" that was implemented long long ago. How about a new plan created this decade. Makes you wonder what else is in this plan. And it's the one and only plan they ever actually achieve. Enrichment. Jokes.
Oh yes and I almost forgot, we'll get em next week.
Just looking around like I always do and found this interesting tidbit in Doron Shorrer, another board member.
On Feb 15, 2016 he bought 12,346 shares on the open market for $.80. Then on May 30, 2016, he turns around and sells the 12,346 shares for $1.52.
https://www.nasdaq.com/symbol/psti/insider-trades?page=2
How can a board member be allowed to do such a transaction in such a short period of time, and almost double his money. I'm sure what was done was legal or something would have been done about it. But it sure stinks like so much else I have discovered.
It was a simple question. What do you expect to get from that?
What do you really expect to gain by asking Allo anything. Have you ever looked at Yahoo board? If not, do yourself a favour and follow it for a bit. They post under disruptive, allogeneic, and many more that I just can't think of. Then they delete these posts. Constantly. They are the same one and openly admit it. And yes, it's the same person here. What could you possibly hope to gain by asking someone who admits to having multiple aliases? Do you think there's any ounce of truth to anything they dream up, or more likely there upon other people's orders, like their boss. Boggles my mind truly.
Do you actually think big negotiations are going on with Sosei? They want it all!!! Any yet to be proven indication they can sink their chops into. Maybe the controller with tentacles everywhere, extended them to Japan to thwart any effort of Pluristem to succeed. Maybe the battles back and forth for everyone who is dying to get a piece of Pluristem, has driven the price up to $11,000,006. Or is it maybe because Sosei wants to see results first. Or maybe they want a board member? A very precious item to Pluristem management. Seems more logical than anything the chosen one throws out there.
Why do most totally ignore and I mean ignore any risk and act like everything is rosy. $30 stock price. Oh wow. Who cares about risks. Did you not hear. It's biotech. That's for just one approval. With 2, should be $200. There is NO statistical evidence in humans that these indication will work. Positive yes, just with stacked odds in the trials, by recruiting people most likely to benefit. Remarkable.
I'm starting to think a majority of people here are cut from the same cloth if you know what I mean.. This board truly is Bizzaro world.
What's really sad in this board are the one'z who try to encourage and promote this stock with statements like I'm buying blocks of 10,000 shares around $2 bucks. Anything under $2 is a steal right. Or after the pump then dump when reality comes back say, I've seen tons of companies do a raise and then shoot right back up. Guess what. It didn't happen did it. And if people actually listened, they'd be well under water.
All of this while entirely fluffing off any risk whatsoever with, it's biotech. Well it's not. It's Pluristem. Want to take a look at the risks, read the Edison report. Don't just look at the parts you want to hear.
Look at the part that talks about the most potential beneficial patients that enrolled in the hip fracture study. The questioning of the size of that market. The need for future dilution. The huge risk of jumping to stage 3 trials. The risk of having zero statistically significant numbers in any human trials with results. Others as well.
And let's not forget the giant risk of putting your money in the hands of people who are incapable of running a Biotech company. You know, with all the questionable clowns and how nobody on this board can come up with any reason whatsoever that justifies their belief that they CAN run a company. Some feeble attempts by one, but easily shot down.
Ask yourself this. How or why would any retail investor try to own 200,000 shares at over a quarter of a million dollars. Someone who is absolutely loaded maybe. But if that were the case, does anyone really think they'd be wasting their time posting here? Not likely.
I'm not sure what you mean by "I'll reconsider" there Happy. Not sure what you read of Zzatt's post that has given you renewed confidence in Pluristem. But it just proves my point.
Not sure what being under $1.40 should be called now. Steal of the century. But trying to lure investors in during pumps and all the way down should be called crime of the century.